Regeneron Pharmaceuticals Inc (NAS:REGN) Stock News, Headlines & Updates
Regeneron Pharmaceuticals Inc Stock News from GuruFocus
- 1
Jul 11, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PRNewswire • 7:00pm
Jul 10, 2024
Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
Marketwired • 3:00pm
Jul 07, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Marketwired • 2:00pm
Jul 03, 2024
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
Marketwired • 12:00am
Jul 02, 2024
Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
GuruFocus Research • 5:01pm
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
PRNewswire • 12:00pm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PRNewswire • 10:00am
Jun 30, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. --Â REGN
Marketwired • 11:00am
Jun 28, 2024
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Marketwired • 6:00am
Jun 27, 2024
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Marketwired • 4:00pm
Jun 26, 2024
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
GlobeNewswire • 5:00pm
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Marketwired • 5:00pm
Jun 25, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PRNewswire • 7:00pm
Jun 22, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Marketwired • 4:00pm
Jun 16, 2024
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
GlobeNewswire • 11:00am
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
Marketwired • 6:00am
Jun 15, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PRNewswire • 8:00am
Jun 13, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Marketwired • 4:00pm
Jun 11, 2024
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Marketwired • 7:00am
Jun 05, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Marketwired • 3:00pm
May 31, 2024
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
Marketwired • 1:00am
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
Marketwired • 12:00am
May 30, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PRNewswire • 5:00pm
May 28, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Marketwired • 3:00pm
May 23, 2024
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
Marketwired • 5:00pm
May 22, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PRNewswire • 4:00pm
May 20, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Marketwired • 5:00pm
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
Marketwired • 2:00pm
May 17, 2024
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Marketwired • 1:00pm
May 16, 2024
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
Business Wire • 3:00pm
May 13, 2024
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
Marketwired • 12:00am
May 08, 2024
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Marketwired • 6:00am
May 06, 2024
Regeneron Announces Investor Conference Presentations
Marketwired • 4:00pm
Why Investors Are Eyeing Regeneron Pharmaceuticals Inc (REGN): The Key Drivers of Market Outperformance and Growth Potential
GuruFocus Research • 10:01am
May 03, 2024
Why Investors Are Eyeing Regeneron Pharmaceuticals Inc (REGN): The Key Drivers of Market Outperformance and Growth Potential
GuruFocus Research • 10:01am
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial Achievements and Strategic Insights
GuruFocus Research • 1:10am
Q1 2024 Regeneron Pharmaceuticals Inc Earnings Call Transcript
GuruFocus Research • 11:13pm
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
GuruFocus Research • 11:08pm
May 02, 2024
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst Revenue Dip
GuruFocus Research • 6:32am
Apr 29, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news